SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending amid community debate about its technology and future prospects, with some users expressing skepticism about eVTOL capabilities and range limitations. Bullish investors are pointing to upcoming events like the California International Air Show and potential military contracts as catalysts for growth. A possible collaboration with Tesla has also surfaced as a point of discussion among investors.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community discusses potential catalysts including upcoming news, partnerships, and the possibility of a major exchange listing. Bullish sentiment is fueled by comparisons to early XRP and anticipation of the Zebec Super App launch. Many believe ZBCN is positioned for significant growth and real-world adoption within the evolving financial landscape.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crypto, CAW, is trending due to community enthusiasm around its meme-based identity, "crow with knife," and its expansion across multiple chains. Community members highlight its strong community and deflationary aspects, with many urging others to add it to their watchlist. Bullish sentiment and repetitive "caw caw" messaging dominate the conversation.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network ($REACT) is trending amid community excitement around its cross-chain automation capabilities and the upcoming sunsetting of $PRQ, which some believe has been suppressing its price. The community is also anticipating new exchange listings and marketing campaigns, while highlighting its strong technology and staking rewards. Discussions include potential price targets and the belief that $REACT is an undervalued gem with significant long-term potential.

Roundhill ETF Trust - Roundhill WeeklyPay Universe ETF

Roundhill WeeklyPay™ Universe ETF

The Roundhill WeeklyPay™ Universe ETF ($WPAY) is trending as investors discuss its weekly dividend payouts and compare it to other high-yield ETFs. Community members are actively sharing dividend amounts and payout schedules, while also debating its valuation and potential for NAV erosion. Some are rotating into $WPAY from other dividend plays, drawn to its promise of consistent income.

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.

Glaukos Corporation

Glaukos ($GKOS) is trending due to positive Phase 3 trial results for its iDose TR glaucoma treatment, which met primary efficacy endpoints and showed a favorable safety profile. The community is actively discussing the potential for this innovative drug delivery system to disrupt the glaucoma treatment market. Analysts are updating ratings and price targets, reflecting optimism about Glaukos's pipeline and market position in ophthalmic therapies.

Investment Managers Series Trust II - Tradr 2X Long UPST Daily ETF

Tradr 2X Long UPST Daily ETF

Traders are actively discussing $UPSX, a 2x leveraged ETF for Upstart, with many highlighting it as a way to amplify potential gains from $UPST, especially amid anticipation of future rate cuts. The community is weighing the risks and rewards of using the ETF, with some expressing concerns about its correlation to the underlying stock and others seeing it as a potential high-reward play. Overall sentiment leans bullish, with some expecting a significant move if $UPST rebounds.

The Hershey Co. engages in the manufacture and marketing of chocolate, sweets, mints and confectionery products. The firm operates through the following segments: North America Confectionery, North America Salty Snacks and International. The North America Confectionery segment is responsible for the traditional chocolate and non-chocolate confectionery market position of the company, as well as its grocery and snacks market positions, in the United States and Canada. The North America Salty Snacks segment is responsible for the salty snack products in the United States. The International segment includes the combination of all other operating segments, including those geographic regions where the company operates outside of North America. Its brands include Hershey's, Reese's, and Kisses. The company was founded by Milton S. Hershey in 1894 and is headquartered in Hershey, PA.

Hershey Company

HSY is trending amid reports of a potential takeover by Mondelez, driving speculation and a notable price surge. While some traders are betting on a continued rise, others anticipate a pullback if the deal doesn't materialize, given concerns about high cocoa prices and potential market overvaluation.

Morgan Stanley operates as a global financial services company. The firm provides investment banking products and services to its clients and customers including corporations, governments, financial institutions, and individuals. It operates through the following segments: Institutional Securities, Wealth Management, and Investment Management. The Institutional Services segment provides financial advisory, capital-raising services, and related financing services on behalf of institutional investors. The Wealth Management segment offers brokerage and investment advisory services covering various types of investments, including equities, options, futures, foreign currencies, precious metals, fixed-income securities, mutual funds, structured products, alternative investments, unit investment trusts, managed futures, separately managed accounts, and mutual fund asset allocation programs. The Investment Management segment provides equity, fixed income, alternative investments, real estate, and merchant banking strategies. The company was founded by Harold Stanley and Henry S. Morgan in 1924 and is headquartered in New York, NY.

Morgan Stanley

Morgan Stanley ($MS) is trending due to a mix of factors, including unusual options activity and analyst ratings adjustments. Community discussions include call options activity, potential share buybacks, and its performance relative to peers in the financial sector. Some traders are noting technical indicators and potential entry points, while others discuss the broader market context.

Tenable Holdings, Inc. engages in the development of security software solutions. It offers Cyber Exposure which is a discipline for managing and measuring cybersecurity risk in the digital era. Its products include tenable.io, tenable.sc, tenable.ot, and nessus professional. The firm delivers solutions in the field of application security, cloud security, compliance, energy, finance, healthcare, and retail. The company was founded by John C. Huffard, Jr. and Renaud M. Deraison in 2002 and is headquartered in Columbia, MD.

Tenable Holdings Inc

Tenable Holdings is trending amid discussions of its potential as an AI protection acquisition target and overall cybersecurity sector dynamics. Community members are weighing the company's merits against competitors, with some expressing disappointment in its muted market response despite positive earnings, while others suggest it's a hidden gem. Additionally, recent analyst rating adjustments and price target updates are contributing to the ongoing conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why

TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty

Investing.com -- TD Securities downgraded Milestone Pharmaceuticals (NASDAQ:MIST) to "Hold" and suspended its price target, citing regulatory uncertainty and commercialization challenges for its lead drug, etripamil, following a Complete Response Letter from the U.S. Food and Drug Administration.The FDA issued a Complete Response Letter for MIST’s etripamil New Drug Application for paroxysmal supraventricular tachycardia (pSVT), citing chemistry, manufacturing, and controls issues. While no safety or efficacy concerns were raised, the agency requested additional data on nitrosamine impurities based on new draft guidance published in September 2024, months after MIST had resubmitted its New Drug Application . The FDA also flagged the need for an inspection at a third-party facility performing release testing, which changed ownership during the New Drug Application review.

Shares of Milestone Pharmaceuticals Inc. (MIST) traded 60% lower on Friday after the Food and Drug Administration (FDA) did <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/03/28/3051260/0/en/FDA-Issues-Complete-Response-Letter-for-Etripamil-for-PSVT.html">not approve</a> its lead investigational product, Cardamyst.The nasal spray is under development to treat episodes of abnormal heart rhythm associated with Paroxysmal supraventricular tachycardia (PSVT).The FDA highlighted two key Chemistry, Manufacturing and Controls (CMC) issues.The regulator asked the company to submit additional information on nitrosamine impurities based on the new draft guidance issued after the New Drug Application (NDA) submission. &nbsp;The agency also said an inspection is required at a facility where the company performed release testing for the product to ensure it complies with Current Good Manufacturing Practices.Milestone Pharmaceuticals CEO Joe Oliveto said that the company is “deeply disappointed” by the letter but remains committed to the potential of the drug in treating patients with PSVT.“Our team is evaluating the feedback provided and intends to request a Type A meeting to discuss the issues raised in the CRL,” Oliveto said. “We are appreciative of the FDA’s efforts and are confident we can collaborate with the agency with the goal of addressing these issues in a resubmission.”The FDA did not raise any concerns regarding the drug’s clinical safety or efficacy, the company said.The nasal spray has been designed as a self-administered rapid response therapy, thereby bypassing the need for immediate medical oversight, it explained.On Stocktwits, retail investor sentiment about Milestone Pharmaceuticals dropped slightly within the ‘extremely bullish’ territory (89/100), while message volume remained at ‘extremely high’ levels over the past 24 hours.<figure class="image"><img style="aspect-ratio:652/152;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_28_at_12_10_06_PM_png_e7518f6d31.webp" alt="MIST's Sentiment Meter and Message Volume as of 12:10 p.m. ET on March 28, 2025 | Source: Stocktwits" width="652" height="152"><figcaption>MIST's Sentiment Meter and Message Volume as of 12:10 p.m. ET on March 28, 2025 | Source: Stocktwits</figcaption></figure>Following the company’s announcement, HC Wainwright kept a ‘Buy’ rating on Milestone pharmaceuticals and noted that the FDA flagged no concerns around the efficacy of the product, thereby reaffirming the integrity of the clinical data.However, the firm expects the product's launch to be delayed until the first half of 2026.<a href="https://stocktwits.com/symbol/MIST">Shares of Milestone Pharmaceuticals</a> fell over 55% this year and by over 45% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/hyperscale-data-shares-drop-despite-completing-first-nvidia-gpu-installation/chJ3iDORbEC">Hyperscale Data Stock Drops Despite Completing First Nvidia GPU Installation – But Retail Turns Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive 

The FDA said an inspection is required at a facility where the company performed release testing for the product to ensure it complies with Current Good Manufacturing Practices.

Equity

Milestone Pharmaceuticals Upgraded to Buy: Here's What You Should Know

Milestone Pharmaceuticals (NASDAQ: MIST) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings...

Milestone  Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference

MONTREAL and CHARLOTTE, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will deliver a company...

Milestone  Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences

MONTREAL and CHARLOTTE, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of...

Milestone's Etripamil Aims to Revolutionize PSVT Treatment

Milestone Pharmaceuticals (MIST) has released an update. Milestone Pharmaceuticals has announced the resubmission of its New Drug Application to th...

Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia

MONTREAL and CHARLOTTE, N.C., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of...

Milestone Pharmaceuticals (NASDAQ:MIST) Stock Rating Reaffirmed by HC Wainwright

Milestone Pharmaceuticals (NASDAQ:MIST  Get Free Report)s stock had its buy rating restated by research analysts at HC Wainwright in a research note issued on Friday...

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update

- On track to resubmit NDA for etripamil in PSVT early 2Q 2024 - Recent financing extends cash runway into 2026 - FDA reiterated prior guidance on regulatory pathway for AFib-RVR, End of Phase 2...

Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.

Milestone Pharmaceuticals Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$2.11
Prev Close	$2.18
Open	$2.23
Dividend Yield	0.00%
50-Day Moving Average	$1.76
Beta	1.06
Avg. Volume	1.07M
PE Ratio	-2.39

52-Week High	$2.75
52-Week Low	$0.6254
Market Capitalization	$179.34M
EPS (Annual)	-$0.6674
Price to Book	-6.36
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

MIST
Milestone Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MIST News

MIST Milestone Pharmaceuticals Inc